ZNTLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Zentalis Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$2.30+0.17 (+7.98%)
Close on Oct 19, 2026
- Market cap
- $164.05M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | -49.5% | |
| Return on assets | – | -52.0% | -38.1% | |
| Current ratio | – | 12.07 | 6.93 | |
| Diluted shares | – | 28M | 72M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Zentalis Pharmaceuticals generated $821.77M from operations and spent $19.44M on capital expenditure, dividends and share buybacks. 49% of that went back into the business.
Generated
$821.77M
Used
$19.44M
Capital expenditure$9.46M49%Dividends$00%Share buybacks$9.98M51%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-246.0%
×Asset turnover0.14×
×Equity multiplier1.27×
=Return on equity, FY2024-42.8%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | -246.0% | 0.14× | 1.27× | -42.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$137.06M
- Cash generatingOperating cash flow above zero-$125.25M
- Return on assets improvedROA up on the prior year-30.1% → -31.8%
- Earnings backed by cashOperating cash flow above net income-$125.25M vs -$137.06M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose7.32 → 6.93
- No dilutionShare count did not rise71M → 72M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.12 → 0.00